SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Aug 12, 2016

Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: Aug. 12, 2016 · CIK: 0001604191 · Accession: 0001415889-16-006784

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-212511

Date
August 12, 2016
Author
Johan M. (Thijs) Spoor
Form
CORRESP
Company
Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)

Letter

azrxcorresp_aug122016.htm

AZURRX BIOPHARMA, INC.

760 Parkside Avenue

Downstate Biotechnology Incubator, Suite 217

Brooklyn, New York 11226

August 12, 2016

VIA EDGAR

Securities and Exchange Commission

100 F Street, NE

Washington, D.C. 20549

Re:

AzurRx BioPharma, Inc. (the “Company”)

Registration Statement on Form S-1

File No. 333-212511

Ladies and Gentlemen:

Reference is made to the Company’s letter, filed as correspondence via EDGAR on August 11, 2016, in which the Company requested acceleration of the effective date of the above-referenced Registration Statement to August 12, 2016, at 5:00 p.m., or as soon thereafter as practicable, in accordance with Rule 461 under the Securities Act of 1933, as amended. We hereby withdraw such request for acceleration of the effective date.

Very truly yours,
AZURRX BIOPHARMA, INC.

Show Raw Text
CORRESP
1
filename1.htm

    azrxcorresp_aug122016.htm

AZURRX BIOPHARMA, INC.

760 Parkside Avenue

Downstate Biotechnology Incubator, Suite 217

Brooklyn, New York 11226

August 12, 2016

VIA EDGAR

Securities and Exchange Commission

100 F Street, NE

Washington, D.C. 20549

 Re:

AzurRx BioPharma, Inc. (the “Company”)

Registration Statement on Form S-1

File No. 333-212511

Ladies and Gentlemen:

Reference is made to the Company’s letter, filed as correspondence via EDGAR on August 11, 2016, in which the Company requested acceleration of the effective date of the above-referenced Registration Statement to August 12, 2016, at 5:00 p.m., or as soon thereafter as practicable,  in accordance with Rule 461 under the Securities Act of 1933, as amended. We hereby withdraw such request for acceleration of the effective date.

 Very truly yours,

 AZURRX BIOPHARMA, INC.

By: /s/ Johan M. (Thijs) Spoor

Name: Johan M. (Thijs) Spoor

Title: President and Chief Executive Officer